A Phase 2 interventional study of empagliflozin and Acetazolamide in Acute Decompensated Heart Failure, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Tanta University · Phase 2, Interventional, and Treatment
The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.
Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
will include 22 patients who will receive 10 mg oral empagliflozin administered simultaneously with the first dose of loop diuretics each day for 3 days
Drug: empagliflozin
will include 22 patients who will receive 500 mg oral acetazolamide administered simultaneously with the first dose of loop diuretics each day for 3 days
Drug: Acetazolamide
will include 22 patients who will receive 5 mg oral metolazone administered simultaneously with the first dose of loop diuretics each day for 3 days
Drug: metolazone
Empagliflozin may augment the natriuretic and aquaretic actions of loop diuretics in patients with acute decompensated heart failure and it does not typically cause electrolyte disturbances and has been shown to improve outcomes in patients with heart failure
Acetazolamide can augment the action of loop diuretics in patients with acute decompensated heart failure
Metolazone can augment the action of loop diuretics in patients with acute decompensated heart failure
The cumulative urine output measured over 3 days
Time frame: 3 days
- The change in serum level of N-terminal pro-brain natriuretic peptide (NT-proBNP)
Blood samples will be collected at baseline and after 4 days
Time frame: 4 days
The change in serum level of Soluble suppression of tumorigenicity 2 (sST2)
Blood samples will be collected at baseline and after 4 days
Time frame: 4 days
The change in urinary level of Tissue inhibitor of metalloproteinases-2 (TIMP-2 )
Urine samples will be collected at baseline and after 3 days
Time frame: 3 days
The change in urinary level of Insulin-like growth factor-binding protein 7 (IGFBP7)
Urine samples will be collected at baseline and after 3 days
Time frame: 3 days
30-day mortality
Proportion of patients who die within 30 days of randomization
Time frame: up to 30 days
Proportion of patients achieving an ADVOR Score ≤ 1 without the need for escalating diuretic strategy
the treating physician will calculate the congestion score, on a scale from 0 to 10 on the basis of the sum of scores for the degree of edema (0 to 4), pleural effusion (0 to 3), and ascites (0 to 3), with higher scores indicating a worse condition on all scales
Time frame: 3 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanta University